Solaris Resources Inc. (CVE:SLS – Get Free Report)’s stock price fell 2.7% during trading on Monday . The stock traded as low as C$5.95 and last traded at C$6.15. 53,313 shares traded hands during trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. HC Wainwright raised Solaris Resources to a “strong-buy” rating in a research report on Monday, August 12th. Maxim Group raised Solaris Resources to a “strong-buy” rating in a report on Wednesday, July 3rd.
View Our Latest Research Report on SLS
Solaris Resources Stock Performance
Solaris Resources (CVE:SLS – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported C($0.16) EPS for the quarter.
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
- Five stocks we like better than Solaris Resources
- Financial Services Stocks Investing
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- How to invest in marijuana stocks in 7 stepsĀ
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Roth IRA Calculator: Calculate Your Potential Returns
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.